Clinical Trials
Several clinical trials evaluate streptavidin across diagnostic and targeted therapeutic settings, encompassing Phase I interventional and observational studies sponsored by academic institutions such as the University of Minnesota, the University of Copenhagen, and the Fred Hutchinson Cancer Center. These studies—with recruitment statuses including completed, actively recruiting, and terminated—investigate biotin interference in diagnostic blood tests for thoracic and parathyroid disorders. Additionally, research targets hematologic malignancies, including B-cell non-Hodgkin lymphomas, acute leukemias, and myelodysplastic syndromes, using pretargeted radioimmunotherapy strategies.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07302880 | RECRUITING | Blood Sample; Interference With Routine Analyical Tests; Biotin Ingestion |
University of Copenhagen |
2026-03-17 | |
| NCT02483000 | TERMINATED | Burkitt Lymphoma; CD20-Positive Neoplastic Cells Present; Diffuse Large B-Cell Lymphoma; Indolent Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory Mature B-Cell Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2017-02-01 | PHASE1 |
| NCT03034707 | COMPLETED | Thoracic Diseases; Parathyroid Diseases |
University of Minnesota |
2016-04 | |
| NCT00988715 | COMPLETED | Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Cytopenia With Multilineage Dysplasia; Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts; Secondary Acute Myeloid Leukemia |
Fred Hutchinson Cancer Center |
2010-04-21 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-05-06)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).